

08/872,527
APS
7/8/99

TERMINAL (ENTER 1, 2, 3, 4, OR ?): 3

```
* * * * *
```

```
Welcome to MESSENGER (APS Text) at USPTO
```

```
The USPTO production files are current through:  
July 06,1999   for U.S. Patent Text Data.  
July 06,1999   for U.S. Current Classification Data.  
July 06,1999   for U.S. Patent Image Data.
```

```
* * * * *
```

```
* PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *
```

```
* * * * *
```

```
More U.S. patent data is now available on APS. The new  
USOCR file contains patents issued in 1970, plus some  
patents that were missing from the USPAT file. See the  
Patents News Folder under the Public Folders in e-mail for  
more information on using the new file. Thank you.
```

```
* * * * *
```

```
DISCLAIMER:
```

```
Neither the United States Government, nor any agency  
thereof, nor any of their contractors, subcontractors or  
employees make any warranty, expressed or implied,  
including any warranty of marketability of fitness for a  
particular purpose; nor assumes any legal liability or  
responsibility for any party's use, or the results of  
such, of the data.
```

```
* * * * *
```

```
Help Desk --> 703-305-9000
```

```
The Help Desk is staffed for APS support 7 days/week.  
Monday through Friday:      6:30am - 9:00pm  
Saturday, Sunday, Holidays: 8:30am - 5:00 pm
```

```
The Help Desk staff at this number will handle all APS  
related questions.
```

```
>>>>>>>>>>>>>>>>>>>>>>>>>><<<<<<<<<<<
```

```
The APS is available:  
    6:30am - 9:00pm Monday through Friday  
    7:30am - 5:00pm Saturday, Sunday, Holidays
```

```
APS is unavailable Thanksgiving Day, Christmas Day,  
and New Year's Day.
```

FILE 'USPAT' ENTERED AT 10:36:41 ON 08 JUL 1999

* * * * *

```

*           U. S.   P A T E N T   T E X T   F I L E           *
*
*   THE WEEKLY PATENT TEXT AND IMAGE DATA IS CURRENT         *
*   THROUGH July 06, 1999                                     *
*
*
* * * * *

```

=> s (tumor?/clm or cancer?/clm) and (TNF?/clm and IFN?/clm)

```

3741 TUMOR?/CLM
2349 CANCER?/CLM
367  TNF?/CLM
169  IFN?/CLM

```

L1 18 (TUMOR?/CLM OR CANCER?/CLM) AND (TNF?/CLM AND IFN?/CLM)

=> t 11 1-18

1. 5,902,732; May 11, 1999, Drug screening process measuring changes in cell volume; Daryl W. Hochman, 435/29, 288.7 [IMAGE AVAILABLE]
2. 5,866,113, Feb. 2, 1999, Medical device with biomolecule-coated surface graft matrix; Marc Hendriks, et al., 424/78.17, 78.18, 486, 487; 427/2.24, 2.25, 2.28, 2.3; 525/78; 530/815, 816 [IMAGE AVAILABLE]
3. 5,863,538, Jan. 26, 1999, Compositions for targeting the vasculature of solid tumors; Philip E. Thorpe, et al., 424/136.1, 138.1, 141.1, 154.1, 155.1, 172.1, 173.1, 174.1, 181.1; 530/387.3, 387.7, 388.22 [IMAGE AVAILABLE]
4. 5,855,866, Jan. 5, 1999, Methods for treating the vasculature of solid tumors; Philip E. Thorpe, et al., 424/1.49, 142.1, 155.1, 156.1, 178.1, 181.1, 183.1; 530/387.1, 388.15, 388.22, 388.8, 391.3, 391.7, 391.9 [IMAGE AVAILABLE]
5. 5,843,435, Dec. 1, 1998, Immunotherapy of cancer with allogeneic lymphocytes; Shimon Slavin, 424/93.71, 85.2, 85.4, 85.5, 85.7, 93.7, 144.1 [IMAGE AVAILABLE]
6. 5,840,839, Nov. 24, 1998, Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein; Rong-Fu Wang, et al., 530/325, 328 [IMAGE AVAILABLE]
7. 5,830,880, Nov. 3, 1998, Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound; Hans-Harald Sedlacek, et al., 514/44; 424/93.2, 450; 435/320.1; 536/24.1 [IMAGE AVAILABLE]
8. 5,776,427, Jul. 7, 1998, Methods for targeting the vasculature of solid tumors; Philip E. Thorpe, et al., 424/1.49, 93.21, 138.1, 143.1, 145.1, 178.1, 179.1, 181.1, 183.1; 530/387.2, 388.2, 388.73, 391.7 [IMAGE AVAILABLE]
9. 5,762,921, Jun. 9, 1998, Composition and methods for the treatment of tumors; Gordon A. Vehar, 424/85.1, 85.2, 85.5, 158.1, 198.1; 514/12; 530/350, 351, 381 [IMAGE AVAILABLE]
10. 5,747,292, May 5, 1998, Chimeric cytokine receptors in lymphocytes; Philip D. Greenberg, et al., 435/69.7, 252.3, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]

11. 5,731,343, Mar. 24, 1998, Method of use of radicicol for treatment of immunopathological disorders; Lili Feng, et al., 514/450 [IMAGE AVAILABLE]
12. 5,725,850, Mar. 10, 1998, Use of CSF-1 to treat tumor burden; Peter Ralph, et al., 424/85.1, 278.1; 514/2, 8, 12, 885; 530/351 [IMAGE AVAILABLE]
13. 5,702,717, Dec. 30, 1997, Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers; Younsik Cha, et al., 424/425, 424, 426, 486, 501; 604/891.1 [IMAGE AVAILABLE]
14. 5,698,194, Dec. 16, 1997, Method for making a medicament for treating secondary immunodeficiency; John Winthrop Hadden, 424/85.1, 85.2, 85.4, 85.5; 435/70.4, 70.5 [IMAGE AVAILABLE]
15. 5,648,219, Jul. 15, 1997, Immortalized dendritic cells; Vivian L. MacKay, et al., 435/6, 29, 325, 355 [IMAGE AVAILABLE]
16. 5,627,052, May 6, 1997, Methods for the production of proteins with a desired function; John W. Schrader, 435/69.6, 465; 530/387.1, 388.24 [IMAGE AVAILABLE]
17. 4,894,334, Jan. 16, 1990, Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria; Arie Ben-Bassat, et al., 435/69.1, 69.5, 69.51, 69.52, 244, 247, 252.33; 536/23.1, 24.1 [IMAGE AVAILABLE]
18. 4,879,111, Nov. 7, 1989, Treatment of infections with lymphokines; Kong-Teck Chong, 424/85.2, 85.1, 85.5 [IMAGE AVAILABLE]

=> s interferon/clm or IFN?/clm

```

          1001 INTERFERON/CLM
          169 IFN?/CLM
L2        1085 INTERFERON/CLM OR IFN?/CLM

```

=> s l2 and (cancer?/clm or tumor?/clm)

```

          2349 CANCER?/CLM
          3741 TUMOR?/CLM
L3        215 L2 AND (CANCER?/CLM OR TUMOR?/CLM)

```

=> s l3 and cell/clm

```

          69562 CELL/CLM
L4        106 L3 AND CELL/CLM

```

=> s l4 not l1

```

L5        96 L4 NOT L1

```

=> t l5 1-5

1. 5,912,005, Jun. 15, 1999, Methods of use of uncoated gel particles; Robert P. Lanza, et al., 424/424, 422, 423; 435/174, 177, 243, 382; 514/866, 885, 907, 953 [IMAGE AVAILABLE]
2. 5,905,089, May 18, 1999, Use of sesquiterpene lactones for treatment

of severe inflammatory disorders; Daniel H. Hwang, et al., 514/468 [IMAGE AVAILABLE]

3. 5,902,799, May 11, 1999, Methods of modulating tissue growth and regeneration; Howard C. Herrmann, et al., 514/58, 21; 530/810, 813, 817 [IMAGE AVAILABLE]

4. 5,891,718, Apr. 6, 1999, Tetracycline inducible/repressible systems; Peter M. Hobart, et al., 435/325, 320.1; 536/24.1 [IMAGE AVAILABLE]

5. 5,874,164, Feb. 23, 1999, Barrier webs having bioactive surfaces; J. Michael Caldwell, 428/306.6; 424/278.1, 443, 499; 428/308.4, 422, 447; 442/76, 79, 82 [IMAGE AVAILABLE]

=> t 15 90-96

90. 4,650,674, Mar. 17, 1987, Synergistic cytotoxic composition; Bharat B. Aggarwal, et al., 424/85.5, 85.4; 435/69.5; 514/12; 930/143, 144 [IMAGE AVAILABLE]

91. 4,622,952, Nov. 18, 1986, Cancer treatment method; Robert T. Gordon, 600/10, 4; 604/20; 607/98 [IMAGE AVAILABLE]

92. 4,613,501, Sep. 23, 1986, Inactivation of viruses in labile blood derivatives; Bernard Horowitz, 530/364; 424/176.1, 530; 435/183, 238; 530/351, 362, 381, 382, 383, 384, 390.1, 392, 394, 412, 831 [IMAGE AVAILABLE]

93. H 22, Feb. 4, 1986, Synergistic effect of chemotherapeutic agents on beta-interferon; Abba A. Creasey, et al., 424/85.6; 435/811; 514/271 [IMAGE AVAILABLE]

94. 4,499,072, Feb. 12, 1985, Process for treating diseases with ODC inhibitors; Sai P. Sunkara, et al., 424/85.7 [IMAGE AVAILABLE]

95. 4,328,207, May 4, 1982, Process for preparing mouse interferon; Kaname Sugimoto, 424/85.7; 435/70.5, 811 [IMAGE AVAILABLE]

96. 4,313,934, Feb. 2, 1982, Physiologically active polysaccharides, production and uses thereof; Kumpei Kitamura, et al., 530/371; 514/889; 530/395 [IMAGE AVAILABLE]

=> s 15 and (tumor necrosis factor/clm or TNF?/clm)

3160 TUMOR/CLM
598 NECROSIS/CLM
27538 FACTOR/CLM
370 TUMOR NECROSIS FACTOR/CLM
((TUMOR(W)NECROSIS(W)FACTOR)/CLM)
367 TNF?/CLM

L6 55 L5 AND (TUMOR NECROSIS FACTOR/CLM OR TNF?/CLM)

=> t 16 1-55

1. 5,912,005, Jun. 15, 1999, Methods of use of uncoated gel particles; Robert P. Lanza, et al., 424/424, 422, 423; 435/174, 177, 243, 382; 514/866, 885, 907, 953 [IMAGE AVAILABLE]

2. 5,905,089, May 18, 1999, Use of sesquiterpene lactones for treatment

of severe inflammatory disorders; Daniel H. Hwang, et al., 514/468 [IMAGE AVAILABLE]

3. 5,902,799, May 11, 1999, Methods of modulating tissue growth and regeneration; Howard C. Herrmann, et al., 514/58, 21; 530/810, 813, 817 [IMAGE AVAILABLE]

4. 5,891,718, Apr. 6, 1999, Tetracycline inducible/repressible systems; Peter M. Hobart, et al., 435/325, 320.1; 536/24.1 [IMAGE AVAILABLE]

5. 5,866,341, Feb. 2, 1999, Compositions and methods for screening drug libraries; Dominic Gregory Spinella, et al., 435/7.1, 4, 5, 6, 7.2, 7.92 [IMAGE AVAILABLE]

6. 5,861,406, Jan. 19, 1999, Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles; Felix Wehrmann, 514/274; 424/85.4, 85.7; 514/2, 21, 359, 386; 544/310; 548/255, 326.5 [IMAGE AVAILABLE]

7. 5,861,290, Jan. 19, 1999, Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders; Mark A. Goldsmith, et al., 424/93.2; 435/320.1; 514/44; 536/23.1, 23.2, 23.5, 23.53, 23.6, 23.7, 23.72, 24.1, 24.5 [IMAGE AVAILABLE]

8. 5,849,586, Dec. 15, 1998, Infective protein delivery system; Michael Kriegler, et al., 435/372; 424/93.2, 93.21; 435/235.1, 320.1, 325, 363, 366, 372.2, 372.3; 536/23.1, 23.5, 23.52 [IMAGE AVAILABLE]

9. 5,837,510, Nov. 17, 1998, Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders; Mark A. Goldsmith, et al., 435/455; 424/93.2; 435/320.1, 456; 514/44; 536/23.1, 23.2, 23.5, 23.53, 23.6, 23.7, 23.72, 24.1, 24.5 [IMAGE AVAILABLE]

10. 5,837,251, Nov. 17, 1998, Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases; Pramod K. Srivastava, 424/193.1, 277.1; 436/543; 514/2; 530/403, 417 [IMAGE AVAILABLE]

11. 5,833,975, Nov. 10, 1998, Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence; Enzo Paoletti, et al., 424/93.2; 435/69.3, 69.5, 69.51, 69.52, 320.1, 456 [IMAGE AVAILABLE]

12. 5,830,464, Nov. 3, 1998, Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy; Pramod K. Srivastava, 424/93.71, 85.1, 85.2, 85.5, 277.1, 278.1; 435/372, 384, 385, 386; 530/350 [IMAGE AVAILABLE]

13. 5,783,566, Jul. 21, 1998, Method for increasing or decreasing transfection efficiency; Kimberly Ann Mislick, 514/44; 424/450; 435/325, 458; 514/1, 2 [IMAGE AVAILABLE]

14. 5,770,222, Jun. 23, 1998, Therapeutic drug delivery systems; Evan C. Unger, et al., 424/450; 264/4.1, 4.3, 4.6; 424/1.21, 9.321, 9.51, 489; 436/829 [IMAGE AVAILABLE]

15. 5,767,156, Jun. 16, 1998, Polyunsaturated fatty acids and uses thereof; Antonio Ferrante, et al., 514/560 [IMAGE AVAILABLE]

16. 5,762,926, Jun. 9, 1998, Method of grafting genetically modified

cells to treat defects, disease or damage of the central nervous system; Fred H. Gage, et al., 424/93.21; 435/69.1, 320.1, 375; 514/44 [IMAGE AVAILABLE]

17. 5,759,535, Jun. 2, 1998, Immunotherapeutic strategies for the treatment of cancer; Edward P. Cohen, 424/93.21; 435/69.1, 320.1 [IMAGE AVAILABLE]

18. 5,750,373, May 12, 1998, Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants; Lisa J. Garrard, et al., 435/69.4, 320.1; 530/399 [IMAGE AVAILABLE]

19. 5,736,129, Apr. 7, 1998, Flow cytometric pharmacosensitivity assay and method of cancer treatment; Rajko D. Medenica, et al., 424/85.4, 85.1, 85.2, 85.5, 85.6; 435/4, 6, 29, 34, 39, 40.5, 325, 347; 436/172 [IMAGE AVAILABLE]

20. 5,714,166, Feb. 3, 1998, Bioactive and/or targeted dendrimer conjugates; Donald A. Tomalia, et al., 424/486, 1.29, 1.33, 1.37, 1.41, 1.49, 9.3, 9.32, 9.322, 9.36, 9.4, 9.42, 9.6, 78.08, 93.1, 178.1, 193.1, 204.1, 234.1, 405, 417, DIG.16; 514/772; 523/105; 525/417 [IMAGE AVAILABLE]

21. 5,707,969, Jan. 13, 1998, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 514/44; 435/6, 69.1, 320.1 [IMAGE AVAILABLE]

22. 5,698,531, Dec. 16, 1997, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 514/44; 435/6, 69.1, 320.1, 456, 458 [IMAGE AVAILABLE]

23. 5,698,530, Dec. 16, 1997, Recombinant virus expressing human carcinoembryonic antigen and methods of use thereof; Jeffrey Schlom, et al., 514/44; 424/93.2; 435/320.1; 536/23.1 [IMAGE AVAILABLE]

24. 5,698,391, Dec. 16, 1997, Methods for synthetic unrandomization of oligomer fragments; Phillip Dan Cook, et al., 435/5, 6 [IMAGE AVAILABLE]

25. 5,651,980, Jul. 29, 1997, Methods of use of uncoated gel particles; Robert P. Lanza, et al., 424/424, 422, 423; 435/174, 177, 243, 382; 514/866, 885, 907, 953 [IMAGE AVAILABLE]

26. 5,650,298, Jul. 22, 1997, Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters; Hermann Bujard, et al., 435/69.7, 320.1, 463; 536/23.4, 24.1 [IMAGE AVAILABLE]

27. 5,650,148, Jul. 22, 1997, Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system; Fred H. Gage, et al., 424/93.2, 93.21; 435/948; 514/44 [IMAGE AVAILABLE]

28. 5,648,467, Jul. 15, 1997, Natural killer cell stimulatory factor; Giorgio Trinchieri, et al., 530/351; 424/85.2; 435/69.52, 803; 530/416, 417 [IMAGE AVAILABLE]

29. 5,641,670, Jun. 24, 1997, Protein production and protein delivery; Douglas A. Treco, et al., 435/254.11, 320.1, 326, 366, 367, 371, 372, 372.2, 372.3 [IMAGE AVAILABLE]

30. 5,624,895, Apr. 29, 1997, Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration; Douglas Sobel, 514/8; 424/85.1, 85.2, 85.4, 85.5, 85.6, 85.7; 514/866 [IMAGE AVAILABLE]
31. 5,602,025, Feb. 11, 1997, Non-tumorigenic cell lines for expression of genes; David W. Barnes, 435/69.1, 69.4, 69.51, 69.52, 69.6, 212, 366, 395, 455 [IMAGE AVAILABLE]
32. 5,580,561, Dec. 3, 1996, Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide; Boris Cercek, et al., 424/145.1, 139.1, 185.1; 514/12, 21; 530/324, 325, 351, 387.9, 388.1, 388.2, 388.25, 388.7, 388.8 [IMAGE AVAILABLE]
33. 5,543,300, Aug. 6, 1996, Method and composition for determining the immunological activity of bioactive substances; Anna Inglot, et al., 435/29; 424/85.1, 195.1; 435/4; 530/351 [IMAGE AVAILABLE]
34. 5,474,930, Dec. 12, 1995, Non-tumorigenic cell lines for expression of genes; David W. Barnes, 435/354, 69.1, 387, 389, 391, 392 [IMAGE AVAILABLE]
35. 5,370,870, Dec. 6, 1994, Method for protection against reactive oxygen species; Grace H. W. Wong, 424/85.1, 85.2; 514/2, 8, 12; 530/351; 930/144 [IMAGE AVAILABLE]
36. 5,362,490, Nov. 8, 1994, Human myelomonocyte interferon-gamma, and process for preparation and use thereof; Masashi Kurimoto, et al., 424/85.5, 85.1, 85.2, 85.6, 85.7; 435/70.5; 530/351, 413 [IMAGE AVAILABLE]
37. 5,264,208, Nov. 23, 1993, Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent; Thomas K. Hughes, Jr., et al., 424/85.1, 85.4 [IMAGE AVAILABLE]
38. 5,256,560, Oct. 26, 1993, Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells; Michael J. P. Lawman, et al., 435/325, 372 [IMAGE AVAILABLE]
39. 5,256,545, Oct. 26, 1993, Sterol Regulatory Elements; Michael S. Brown, et al., 435/69.1, 252.3, 320.1, 358, 464, 465; 536/24.1 [IMAGE AVAILABLE]
40. 5,223,408, Jun. 29, 1993, Method for making variant secreted proteins with altered properties; David V. Goeddel, et al., 435/69.3, 69.4, 69.52, 69.6, 69.7, 189, 195, 215, 216, 226, 455 [IMAGE AVAILABLE]
41. 5,188,959, Feb. 23, 1993, Extracellular matrix protein adherent T cells; Allan B. Haberman, 435/6, 4, 332, 373, 385, 402 [IMAGE AVAILABLE]
42. 5,147,638, Sep. 15, 1992, Inhibition of tumor growth by blockade of the protein C system; Charles T. Esmon, et al., 424/85.1, 85.2, 85.4, 85.5, 152.1, 172.1, 282.1; 435/212; 514/2, 8, 12; 530/351, 381, 388.25, 389.3 [IMAGE AVAILABLE]
43. 5,145,677, Sep. 8, 1992, Process for treatment of diseases; Johann-Friedrich von Eichborn, et al., 424/85.5, 85.1, 85.2 [IMAGE AVAILABLE]
44. 5,128,126, Jul. 7, 1992, Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of

preneoplastic lesions; Jacques Boniver, 424/85.5, 85.1, 85.2, 85.4 [IMAGE AVAILABLE]

45. 5,126,148, Jun. 30, 1992, Process to prepare metastasis-inhibitory factor; Masashi Kurimoto, et al., 424/577 [IMAGE AVAILABLE]

46. 5,124,147, Jun. 23, 1992, Method for the treatment of endotoxic shock in a mammal; Allan Wissner, et al., 424/145.1, 150.1, 158.1, 164.1 [IMAGE AVAILABLE]

47. 4,935,363, Jun. 19, 1990, Sterol regulatory elements; Michael S. Brown, et al., 435/69.1, 41, 69.4, 69.5, 69.51, 69.52, 207, 212, 226, 375, 455; 536/23.2, 23.5, 23.51, 23.52 [IMAGE AVAILABLE]

48. 4,929,442, May 29, 1990, Compositions suitable for human topical application including a growth factor and/or related materials; Maxwell M. Powell, 424/85.2, 85.1, 85.4, 85.7 [IMAGE AVAILABLE]

49. 4,886,655, Dec. 12, 1989, Method of detecting infection or immunity in ruminants; John F. T. Griffin, 435/4, 7.24, 7.92, 13, 29; 436/501 [IMAGE AVAILABLE]

50. 4,849,506, Jul. 18, 1989, Leukoregulin, an antitumor lymphokine, and its therapeutic uses; Janet H. Ransom, et al., 530/351; 424/85.1; 435/70.3, 70.4; 514/2, 8, 21; 530/350, 827 [IMAGE AVAILABLE]

51. 4,843,004, Jun. 27, 1989, Method for the production of human T-T cell hybrids and production suppressor factor by human T-T cell hybrids; Chris Platsoucas, 435/451, 69.5, 449, 948; 530/351, 837 [IMAGE AVAILABLE]

52. 4,828,830, May 9, 1989, Method and composition for prophylaxis and treatment of viral infections; Grace H. W. Wong, 424/85.5, 85.1; 514/2 [IMAGE AVAILABLE]

53. 4,822,605, Apr. 18, 1989, Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like; Maxwell M. Powell, 424/85.2, 85.1, 85.4, 85.5, 85.7 [IMAGE AVAILABLE]

54. 4,785,077, Nov. 15, 1988, Substantially pure cytotoxicity triggering factor; Richard Kornbluth, et al., 530/351; 424/85.1, 85.4; 435/70.3, 70.4, 375, 948; 530/350, 827 [IMAGE AVAILABLE]

55. 4,650,674, Mar. 17, 1987, Synergistic cytotoxic composition; Bharat B. Aggarwal, et al., 424/85.5, 85.4; 435/69.5; 514/12; 930/143, 144 [IMAGE AVAILABLE]

=> logoff hold

SESSION WILL BE HELD FOR 30 MINUTES
U.S. Patent & Trademark Office SESSION SUSPENDED AT 10:44:18 ON 08 JUL 199